UY26291A1 - Compuestos químicos xxii - Google Patents
Compuestos químicos xxiiInfo
- Publication number
- UY26291A1 UY26291A1 UY26291A UY26291A UY26291A1 UY 26291 A1 UY26291 A1 UY 26291A1 UY 26291 A UY26291 A UY 26291A UY 26291 A UY26291 A UY 26291A UY 26291 A1 UY26291 A1 UY 26291A1
- Authority
- UY
- Uruguay
- Prior art keywords
- chemical compounds
- disorders
- treatment
- nervous system
- central nervous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Un compuesto químico de fórmula (I): y las sales, compuestos de adición y procedicamentos farmacéuticamente aceptables de éstos; y el uso de éstos en terapia, particularmente como agonistas o antagonistas de un receptor de 5-HT, particularmente un receptor de 5-HT2c, por ejemplo en el tratamiento de trastornos del sistema nervioso central, dano al sistema nervioso central, trastornos cardiovasculares, trastornos gastrointestinales, diabetes insípida y apnea del sueno, y particularmente para el tratamiento de la obesidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9918962.3A GB9918962D0 (en) | 1999-08-11 | 1999-08-11 | Chemical compounds xxii |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26291A1 true UY26291A1 (es) | 2001-03-16 |
Family
ID=10858982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26291A UY26291A1 (es) | 1999-08-11 | 2000-08-11 | Compuestos químicos xxii |
Country Status (21)
Country | Link |
---|---|
US (1) | US6706750B1 (es) |
EP (1) | EP1202965B1 (es) |
JP (1) | JP2003507367A (es) |
KR (1) | KR100740172B1 (es) |
CN (1) | CN1187330C (es) |
AR (1) | AR037222A1 (es) |
AT (1) | ATE279392T1 (es) |
AU (1) | AU773337B2 (es) |
BR (1) | BR0013307A (es) |
CA (1) | CA2377646A1 (es) |
DE (1) | DE60014918T2 (es) |
DK (1) | DK1202965T3 (es) |
ES (1) | ES2228588T3 (es) |
GB (1) | GB9918962D0 (es) |
MX (1) | MXPA01013235A (es) |
PE (1) | PE20010574A1 (es) |
PT (1) | PT1202965E (es) |
TR (1) | TR200200352T2 (es) |
UY (1) | UY26291A1 (es) |
WO (1) | WO2001012603A1 (es) |
ZA (1) | ZA200110217B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
GB9918965D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
AU2002221670B2 (en) * | 2000-10-16 | 2006-11-02 | F. Hoffmann-La Roche Ag | Indoline derivatives and their use as 5-HT2 receptor ligands |
CA2465534C (en) * | 2000-11-02 | 2009-10-27 | Nigel H. Greig | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof |
AR031200A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados |
US6858604B2 (en) | 2000-11-03 | 2005-02-22 | Wyeth | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
US6777407B2 (en) | 2000-11-03 | 2004-08-17 | Wyeth | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
JP4204315B2 (ja) | 2000-11-20 | 2009-01-07 | ビオヴィトルム・アクチボラゲット(プブリクト) | セロトニン5−ht2レセプターのアンタゴニストとしてのピペラジニルピラジン化合物 |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US7087636B2 (en) * | 2001-12-19 | 2006-08-08 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function |
TW200307540A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
IL165220A0 (en) | 2002-06-19 | 2005-12-18 | Biovitrum Ab | Novel compounds, their use and preparation |
WO2004063156A1 (en) * | 2003-01-08 | 2004-07-29 | Biovitrum Ab | Novel indole derivates as fabp-4 inhibitors |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
EA016575B1 (ru) | 2004-03-15 | 2012-06-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Производные карболина, полезные в ингибировании ангиогенеза |
US8076353B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
CA2559545A1 (en) * | 2004-03-15 | 2005-09-29 | Ptc Therapeutics, Inc. | Tetra-cyclic carboline derivatives for inhibiting angiogenesis |
WO2006012310A2 (en) * | 2004-06-25 | 2006-02-02 | Genzyme Corporation | Carbazole derivatives for treating polycystic kidney disease |
EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
CN101102765A (zh) * | 2004-11-23 | 2008-01-09 | Ptc医疗公司 | 通过翻译控制抑制vegf产生的活性物质四氢咔唑 |
MX2007006179A (es) | 2004-11-23 | 2007-06-20 | Ptc Therapeutics Inc | Tetrahidrocarbazoles como agentes activos para inhibir la produccion del factor de crecimiento endotelial vascular por control de la traduccion. |
GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
AR054849A1 (es) | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
WO2023114238A1 (en) * | 2021-12-15 | 2023-06-22 | Delix Therapeutics, Inc. | Aryloxy psychoplastogens and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2541211A (en) | 1948-10-15 | 1951-02-13 | Searle & Co | Tertiary-aminoalkyl-tetrahydrocarbazoles |
US2687414A (en) * | 1948-11-26 | 1954-08-24 | Searle & Co | Method for producing aromatic aminoalkyl amines |
DE930988C (de) | 1953-01-01 | 1955-07-28 | Bayer Ag | Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen |
US3151120A (en) * | 1961-08-15 | 1964-09-29 | Ciba Geigy Corp | Thieno [3, 2-b] indole esters and amides |
US3133930A (en) * | 1961-08-15 | 1964-05-19 | Ciba Geigy Corp | Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids |
US3329571A (en) * | 1961-10-24 | 1967-07-04 | American Home Prod | Methods for treating depression |
NL133522C (es) | 1961-10-24 | |||
US3142678A (en) * | 1962-01-09 | 1964-07-28 | American Home Prod | Amino substituted penthienoindoles |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
TW270114B (es) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
TW403738B (en) | 1994-08-12 | 2000-09-01 | Hoffmann La Roche | Tricyclic pyrazole derivatives |
AU5343298A (en) * | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
-
1999
- 1999-08-11 GB GBGB9918962.3A patent/GB9918962D0/en not_active Ceased
-
2000
- 2000-08-04 CN CNB00811515XA patent/CN1187330C/zh not_active Expired - Fee Related
- 2000-08-04 DK DK00951697T patent/DK1202965T3/da active
- 2000-08-04 ES ES00951697T patent/ES2228588T3/es not_active Expired - Lifetime
- 2000-08-04 AT AT00951697T patent/ATE279392T1/de not_active IP Right Cessation
- 2000-08-04 MX MXPA01013235A patent/MXPA01013235A/es active IP Right Grant
- 2000-08-04 CA CA002377646A patent/CA2377646A1/en not_active Abandoned
- 2000-08-04 WO PCT/GB2000/003011 patent/WO2001012603A1/en active IP Right Grant
- 2000-08-04 TR TR2002/00352T patent/TR200200352T2/xx unknown
- 2000-08-04 BR BR0013307-8A patent/BR0013307A/pt not_active Application Discontinuation
- 2000-08-04 US US10/009,568 patent/US6706750B1/en not_active Expired - Fee Related
- 2000-08-04 EP EP00951697A patent/EP1202965B1/en not_active Expired - Lifetime
- 2000-08-04 AU AU64555/00A patent/AU773337B2/en not_active Ceased
- 2000-08-04 KR KR1020027001108A patent/KR100740172B1/ko not_active IP Right Cessation
- 2000-08-04 DE DE60014918T patent/DE60014918T2/de not_active Expired - Fee Related
- 2000-08-04 PT PT00951697T patent/PT1202965E/pt unknown
- 2000-08-04 JP JP2001517501A patent/JP2003507367A/ja active Pending
- 2000-08-09 PE PE2000000807A patent/PE20010574A1/es not_active Application Discontinuation
- 2000-08-10 AR ARP000104120A patent/AR037222A1/es unknown
- 2000-08-11 UY UY26291A patent/UY26291A1/es not_active Application Discontinuation
-
2001
- 2001-12-12 ZA ZA200110217A patent/ZA200110217B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001012603A1 (en) | 2001-02-22 |
AU6455500A (en) | 2001-03-13 |
JP2003507367A (ja) | 2003-02-25 |
DK1202965T3 (da) | 2005-02-14 |
GB9918962D0 (en) | 1999-10-13 |
AR037222A1 (es) | 2004-11-03 |
KR20020015078A (ko) | 2002-02-27 |
PT1202965E (pt) | 2005-01-31 |
PE20010574A1 (es) | 2001-05-21 |
ZA200110217B (en) | 2002-12-12 |
CN1368960A (zh) | 2002-09-11 |
EP1202965B1 (en) | 2004-10-13 |
ATE279392T1 (de) | 2004-10-15 |
AU773337B2 (en) | 2004-05-20 |
DE60014918T2 (de) | 2005-10-13 |
DE60014918D1 (de) | 2004-11-18 |
US6706750B1 (en) | 2004-03-16 |
CN1187330C (zh) | 2005-02-02 |
ES2228588T3 (es) | 2005-04-16 |
BR0013307A (pt) | 2002-05-28 |
KR100740172B1 (ko) | 2007-07-16 |
TR200200352T2 (es) | 2002-06-21 |
MXPA01013235A (es) | 2002-06-04 |
EP1202965A1 (en) | 2002-05-08 |
CA2377646A1 (en) | 2001-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26291A1 (es) | Compuestos químicos xxii | |
UY26290A1 (es) | Compuestos químicos xxi | |
PT1147110E (pt) | Derivados de pirazino (aza)-indol | |
TR200200648T2 (tr) | Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri. | |
CR6616A (es) | Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas | |
ATE289593T1 (de) | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden | |
RS65704A (en) | Aza-arylpiperazines | |
NO20062139L (no) | Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister | |
NO20075623L (no) | Benzodioksan- og benzodioksolanderivater og deres anvendelse | |
NO20076418L (no) | Heterocyclic compounds as agonists for the thyroid receptor | |
UY27097A1 (es) | Derivados del indol | |
UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
NZ525700A (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor | |
MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
TW200740787A (en) | (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones | |
MX2008002062A (es) | Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen. | |
ATE307127T1 (de) | 2,4-substituierte pyridinderivate | |
BRPI0411699A (pt) | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos | |
ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
DE602004011394D1 (en) | Thiazolderivate | |
AR036208A1 (es) | Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos | |
NI200700032A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20110217 |